PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 11(3): 270-273
1991
© 1991 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dagogo-Jack, S
Right arrow Articles by Kendall-Taylor, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dagogo-Jack, S
Right arrow Articles by Kendall-Taylor, P
Peritoneal Dialysis International, Vol 11, Issue 3, 270-273
Copyright © 1991 by International Society for Peritoneal Dialysis

Articles

Increased salivary concentration of human epidermal growth factor in patients undergoing CAPD

S Dagogo-Jack, RS Rodger, and P Kendall-Taylor

Department of Nephrology, Washington University School of Medicine, St. Louis, Missouri 63110.

Epidermal growth factor (EGF) was measured in the saliva of 36 patients with chronic renal failure (CRF) and 29 matched control subjects. Salivary EGF in controls was 0.65 +/- 0.009 nmol/L compared with 0.99 +/- 0.24 nmol/L in nondialyzed CRF patients, 1.15 +/- 0.23 in hemodialyzed patients and 1.96 +/- 0.25 (p less than 0.01, Wilcoxon Rank Sum Test) in CAPD-treated patients. On Sephadex chromatography, the major peak of immunoreactive EGF from patient and control saliva samples coeluted with purified human EGF. We conclude that salivary concentrations of human EGF are significantly elevated in end-stage renal failure, particularly in patients treated by CAPD.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 1991 by Multimed Inc.